摘要
目的 探讨溃疡性结肠炎采用美沙拉嗪联合益生菌治疗的效果。方法 随机把136例溃疡性结肠炎患者分成两组,68例观察组和68例对照组。给予对照组美沙拉嗪肠溶片治疗,给予观察组美沙拉嗪联合双歧杆菌三联活菌胶囊治疗。对比两组症状分数、镜检分数、临床疗效和超氧化物歧化酶(SOD)、血清脂质过氧化物(LPO)、白介素-23(IL-23)、白介素-17(IL-17)水平。结果 治疗后,对比两组症状分数和镜检分数,观察组(2.48±0.78)分、(1.05±0.31)分明显低于对照组(4.35±1.06)分、(1.61±0.55)分,具有显著差异(P<0.05)。治疗后,对比两组的SOD、LPO、IL-23、IL-17,观察组各项指标均明显好于对照组,差异明显(P<0.05)。对比两组的治疗总有效率,观察组明显高于对照组,差异明显(P<0.05)。结论 对于溃疡性结肠炎采用美沙拉嗪联合益生菌治疗,具有显著效果,可以有效控制患者的症状,使患者的病情得到改善,对各项指标进行调节,提高了患者的生活质量,加快了患者的康复。
关键词: 溃疡性结肠炎;双歧杆菌三联活菌胶囊;美沙拉嗪;炎性指标
Abstract
Objective To investigate the effect of mesalazine combined with probiotics in the treatment of ulcerative colitis. Methods 136 patients with ulcerative colitis were randomly divided into observation group (n = 68) and control group (n = 68). The control group was treated with mesalazine enteric-coated tablets, and the observation group was treated with mesalazine combined with bifidobacterium triple viable capsules. The symptom scores, microscopic examination scores, clinical efficacy and the levels of superoxide dismutase (SOD), serum lipid peroxides (LPO), interleukin-23 (IL-23) and interleukin-17 (IL-17) were compared between the two groups. Results After treatment, the symptom scores and microscopic examination scores of the two groups were compared. The scores of the observation group (2.48±0.78) and (1.05±0.31) were significantly lower than those of the control group (4.35±1.06) and (1.61±0.55), with significant differences (P<0.05). After treatment, the SOD, LPO, IL-23 and IL-17 of the two groups were compared, and the indexes of the observation group were significantly better than those of the control group, and the differences were significant (P<0.05). The total effective rate of the two groups was significantly higher in the observation group than in the control group (P<0.05). Conclusion s The treatment of ulcerative colitis with mesalazine combined with probiotics has a significant effect, can effectively control the symptoms of patients, make the patient's condition improved, adjust the indicators, improve the quality of life of patients, accelerate the recovery of patients.
Key words: Ulcerative colitis; Bifidobacterium triple viable capsule; Mesalazine; Inflammatory indicators
参考文献 References
[1] 庞亮. 美沙拉嗪联合益生菌治疗溃疡性结肠炎疗效观察[J]. 医学信息, 2017, 30(5):123-124.
[2] 路改英. 美沙拉嗪联合益生菌治疗溃疡性结肠炎疗效及对炎症因子的影响[J]. 内蒙古医学杂志, 2018(12): 1489-1490.
[3] 王永飞. 美沙拉嗪肠溶片联合益生菌制剂对溃疡性结肠炎的影响[J]. 实用中西医结合临床, 2018, 18(11): 20-22.
[4] 蒋琦, 刘怡, 吴巧艳, 等. 美沙拉嗪结合益生菌治疗溃疡性结肠炎的疗效观察[J]. 中国现代医生, 2018, 56(15):37-40.
[5] 闫爱华. 美沙拉嗪联合益生菌治疗溃疡性结肠炎的疗效观察[J].微量元素与健康研究, 2018, 35(4):17-19.
[6] 白冰. 益生菌联合美沙拉嗪治疗溃疡性结肠炎的临床疗效观察[J]. 中国医药指南, 2015(21):97.
[7] 王玉华. 美沙拉嗪联合益生菌治疗溃疡性结肠炎效果观察[J]. 中外医学研究, 2019, 17(4):28-29.
[8] 李博. 美沙拉嗪联合益生菌治疗溃疡性结肠炎的疗效分析[J]. 中外医疗, 2019, 38(1):10-12.
[9] 陆韵竹. 美沙拉嗪和肠道益生菌的联合应用在溃疡性结肠炎治疗中的应用效果[J]. 医药卫生(引文版), 2016,13(2):155-155.
[10] 蒋梦园, 张英剑. 益生菌联合美沙拉嗪治疗溃疡性结肠炎疗效的Meta分析[J]. 现代消化及介入诊疗, 2020, 25(1):7.
[11] 庞亮. 美沙拉嗪联合益生菌治疗溃疡性结肠炎疗效观察[J]. 医学信息, 2017, 30(5):2.
[12] 彭强. 美沙拉嗪联合肠道益生菌对溃疡性结肠炎的治疗价值研究[J]. 海峡药学, 2017, 29(12):2.
[13] 卢战辉, 白阳秋. 美沙拉嗪联合益生菌治疗溃疡性结肠炎临床观察[J]. 社区医学杂志, 2020,21(17):4.
[14] 林易里. 美沙拉嗪联合肠道益生菌对溃疡性结肠炎的治疗价值分析[J]. 中外医学研究, 2020, 18(10):2.